Navigation Links
Neurocrine Biosciences Reports Third Quarter 2008 Results
Date:10/28/2008

2008 2007

(unaudited)

Cash, cash equivalents and marketable securities $96,949 $179,385

Other current assets 1,861 3,563

Total current assets 98,810 182,948

Property and equipment, net 77,309 82,598

Long-term investments 21,255 -

Restricted cash 6,441 6,399

Other non-current assets 3,918 4,709

Total assets $207,733 $276,654

Current liabilities $18,975 $29,907

Long-term liabilities 16,366 19,305

Leaseback financing obligation 108,745 108,745

Stockholders' equity 63,647 118,697

Total liabilities and stockholders' equity $207,733 $276,654


'/>"/>
SOURCE Neurocrine Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Webcast Alert: Neurocrine Announces 3Q 08 Financial Results
2. Neurocrine Biosciences to Present at the Oppenheimer 19th Annual Healthcare Conference
3. Neurocrine Biosciences Announces Conference Call and Webcast to Present Third Quarter 2008 Financial Results
4. Neurocrine Biosciences to Present at the UBS Global Life Sciences Conference
5. Neurocrine Biosciences to Present at Thomas Weisel Healthcare Conference and the NewsMakers in the Biotech Industry Conference
6. Neurocrine Biosciences Reports Second Quarter 2008 Results
7. Neurocrine Biosciences Announces Conference Call and Webcast To Present Second Quarter 2008 Financial Results
8. Neurocrine Biosciences to Present at the 2008 Citi Investment Research Global Health Care Conference
9. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2008 Financial Results
10. Neurocrine Biosciences Announces Conference Call and Webcast to Present Fourth Quarter and Year End 2007 Financial Results
11. Neurocrine Announces Appointment of Kevin Gorman, Ph.D., as President and Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Dr. Greg Leyer of UAS Labs recently was ... Pre-Conference seminar on probiotics in San Diego, CA. , ... conference for health care professionals. This year’s pre-conference seminar was ... in health. Dr. Leyer spoke about the emerging topics and ...
(Date:1/22/2015)... NEW BRUNSWICK , Nueva Jersey , 22 ... Award for Biomedical Research abre hoy su llamada ... las personas cuya investigación científica ha hecho, o tiene ... de la salud humana. Las nominaciones se aceptarán hasta ...
(Date:1/22/2015)... Jan. 22, 2015  Derma Sciences, Inc. (Nasdaq: ... on advanced wound care, announces that AMNIOEXCEL® and ... been added to the Premier, Inc. Regenerative Skin ... for the AMNIOEXCEL® and AMNIOMATRIX® product lines, which ...
(Date:12/24/2014)... , Dec. 24, 2014  Vermillion, Inc. (Nasdaq:   ... disease, announced today that the Company closed its ... Investment Management, Jack W. Schuler , Birchview ... were $10.5 million, before offering expenses.  The proceeds ...
Breaking Biology Technology:El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 3El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3
... Funds Will be Used to ... Designed to Drive the Widespread Adoption of Personalized ... Against Infectious Disease Biocartis, a company ... designed to drive the widespread adoption of personalized ...
... iBio, Inc. (NYSE AMEX: ... technology to produce full length as well as a modified form ... esterase inhibitor is an Orphan Drug approved by the FDA to ... disorder caused by low levels of C1 esterase inhibitor that causes ...
... AMSTERDAM, November 17, 2011 Amsterdam Molecular ... human gene therapy, today provided its non-audited business update ... summarizes material events and AMT,s financial position for the ... , Glybera® Marketing Authorisation Application filed for ...
Cached Biology Technology:Biocartis Completes EUR 71 Million (USD 100 Million) Series C Fund Raising 2Biocartis Completes EUR 71 Million (USD 100 Million) Series C Fund Raising 3Biocartis Completes EUR 71 Million (USD 100 Million) Series C Fund Raising 4iBioLaunch™ Technology Successfully Applied to Modified C1 Inhibitor 2iBioLaunch™ Technology Successfully Applied to Modified C1 Inhibitor 3Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011 2Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011 3Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011 4
(Date:1/22/2015)... 2015  Today, FreeWavz ( www.FreeWavz.com ), the developer ... on Fundable, https://www.fundable.com/freewavz . FreeWavz will be ... to meet customer demand. Logo - ... Invented by Dr. ...
(Date:1/22/2015)... Jan. 20, 2015 NXT-ID, Inc. (NASDAQ: NXTD and ... reports on the recent success of the Wocket™ smart wallet at CES ... smart wallet was named as one of the "11 Hot Products at ... Products Launched At CES So Far" by Newseveryday.com and "The top 10 ...
(Date:1/22/2015)... DUBLIN , Jan. 22, 2015 Research and ... the addition of the "Global Wearable Technologies ... Growth, Share, Overview, Trends and Forecast 2014-2020" ... Wearable Technologies are smart devices that can be ...
Breaking Biology News(10 mins):FreeWavz Launches on Fundable to Drive Speed-to-Market in 2015 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 3Global Wearable Technologies Market and Applications, Opportunities, Industry Analysis, Segmentation, Size, Growth, Share, Overview, Trends and Forecast 2014-2020 2
... received a $7.9 million federal grant to acquire a superconducting ... researchers unravel the mysteries of molecules and develop new agents ... among the largest of its kind ever awarded by the ... the National Institutes of Health. The funds were made available ...
... types of skin cancer but it accounts for the majority of ... rate for early stage melanoma is very high (98 percent), but ... there is recurrence. So a great deal rides on the ... as little tissue as possible while obtaining "clean margins" all around ...
... COLLEGE PARK, Md. - The University of Maryland, ... University of Maryland Baltimore County, has received a $7.9 ... Nuclear Magnetic Resonance (NMR) magnet that will help researchers ... to treat cancer, AIDS and other diseases. The ...
Cached Biology News:University of Maryland School of Medicine receives $7.9 million grant for 'super' research magnet 2Seeing melanoma 2Seeing melanoma 3University of Maryland partnership receives $7.9M from NIH for superconducting research magnet 2University of Maryland partnership receives $7.9M from NIH for superconducting research magnet 3
Wheat Germ Agglutinin (WGA) PS SPA Imaging Bead, 2 g. Category: Leadseeker Beads....
... The steadylite plus assay system ... assay sensitivity, Designed for batch-processing ... for higher density microplates such ... Odor free, Convenient storage conditions ...
... The steadylite plus assay system ... assay sensitivity, Designed for batch-processing ... for higher density microplates such ... Odor free, Convenient storage conditions ...
Functionally tested for consistent G-banding of chromosomes....
Biology Products: